Zobrazeno 1 - 10
of 86
pro vyhledávání: '"L. N. Harris"'
Autor:
A. S. Mansfield, Z. Wei, R. Mehra, A. T. Shaw, C. H. Lieu, P. M. Forde, A. E. Drilon, E. P. Mitchell, J. J. Wright, N. Takebe, E. Sharon, D. Hovelson, S. Tomlins, J. Zeng, K. Poorman, N. Malik, R. J. Gray, S. Li, L. M. McShane, L. V. Rubinstein, D. Patton, P. M. Williams, S. R. Hamilton, B. A. Conley, C. L. Arteaga, L. N. Harris, P. J. O’Dwyer, A. P. Chen, K. T. Flaherty
Publikováno v:
npj Precision Oncology, Vol 6, Iss 1, Pp 1-6 (2022)
Abstract The NCI-MATCH was designed to characterize the efficacy of targeted therapies in histology-agnostic driver mutation-positive malignancies. Sub-protocols F and G were developed to evaluate the role of crizotinib in rare tumors that harbored e
Externí odkaz:
https://doaj.org/article/3cae99beef0c4a4abe8621283988fc92
Publikováno v:
Journal of fish biology. 84(1)
Three populations of Arctic charr Salvelinus alpinus from southern Baffin Island were previously identified to display variable migratory phenotypes, with an anadromous component of the population and another remaining resident in fresh water. In thi
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::89783dc560c63d68014b3ca4236f6c28
https://pubmed.ncbi.nlm.nih.gov/24383802
https://pubmed.ncbi.nlm.nih.gov/24383802
Publikováno v:
American Journal of Enology and Viticulture. 42:109-112
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::6f8211b6419fd7a13f45ecafada4983a
https://doi.org/10.5344/ajev.1991.42.2.109
https://doi.org/10.5344/ajev.1991.42.2.109
Publikováno v:
American Journal of Enology and Viticulture. 42:103-108
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::8f74c2c65e49e176759533c303a6eb61
https://doi.org/10.5344/ajev.1991.42.2.103
https://doi.org/10.5344/ajev.1991.42.2.103
Publikováno v:
Clinical genetics. 69(5)
Although social and ethical issues related to the storage and use of biologic specimens for genetic research have been discussed extensively in the medical literature, few empiric data exist describing patients' views. This qualitative study explored
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::fd72a6291f5dc52e4765d1d9e629b1a1
https://pubmed.ncbi.nlm.nih.gov/16650074
https://pubmed.ncbi.nlm.nih.gov/16650074
Autor:
C L, Vogel, M A, Cobleigh, D, Tripathy, J C, Gutheil, L N, Harris, L, Fehrenbacher, D J, Slamon, M, Murphy, W F, Novotny, M, Burchmore, S, Shak, S J, Stewart
Publikováno v:
Oncology. 61
The pivotal phase II and III Herceptin trials proved the efficacy and safety of second- or third-line single-agent Herceptin and first-line Herceptin in combination with chemotherapy, respectively. In the current trial, 114 patients were randomized t
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::d019390a0959b26f4d4b15a2cca1a8f5
https://pubmed.ncbi.nlm.nih.gov/11694786
https://pubmed.ncbi.nlm.nih.gov/11694786
Publikováno v:
Clinical cancer research : an official journal of the American Association for Cancer Research. 7(6)
ErbB2 (HER-2) gene amplification and overexpression have been shown to predict a better outcome with doxorubicin-based chemotherapy as opposed to alkylator-based chemotherapy in early stage breast cancer. To understand the mechanism of differential r
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::28690a632666c95ee238169091222464
https://pubmed.ncbi.nlm.nih.gov/11410482
https://pubmed.ncbi.nlm.nih.gov/11410482
Autor:
C, Vogel, M A., Cobleigh, D, Tripathy, J C., Gutheil, L N., Harris, L, Fehrenbacher, D J., Slamon, M, Murphy, W F., Novotny, M, Burchmore, S, Shak, S J., Stewart
Publikováno v:
European journal of cancer (Oxford, England : 1990). 37
Following confirmation of the appropriate dosage, safety and potential efficacy of Herceptin(R) (trastuzumab) in small-scale phase I and II trials involving patients with refractory disease, a large trial was conducted in 222 patients with breast can
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::ef6c5e25feb25417c93d3b41d689f072
https://pubmed.ncbi.nlm.nih.gov/11342197
https://pubmed.ncbi.nlm.nih.gov/11342197
Autor:
C, Vogel, M A, Cobleigh, D, Tripathy, J C, Gutheil, L N, Harris, L, Fehrenbacher, D J, Slamon, M, Murphy, W F, Novotny, M, Burchmore, S, Shak, S J, Stewart
Publikováno v:
European journal of cancer (Oxford, England : 1990). 37
Following confirmation of the appropriate dosage, safety and potential efficacy of Herceptin(trastuzumab) in small-scale phase I and II trials involving patients with refractory disease, a large trial was conducted in 222 patients with breast cancer
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::4ad89f4ece0947cdae3021000cb5f160
https://pubmed.ncbi.nlm.nih.gov/11167088
https://pubmed.ncbi.nlm.nih.gov/11167088
Publikováno v:
Clinical cancer research : an official journal of the American Association for Cancer Research. 4(4)
HER2 (erbB-2) proto-oncogene amplification and/or overexpression correlate with poor prognosis in many malignancies. The precise biological role of this oncogenic signaling pathway (which also involves the HER4 gene) in breast cancer is unclear. One
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::a56a65c974590cdeda98f232dcee6839
https://pubmed.ncbi.nlm.nih.gov/9563896
https://pubmed.ncbi.nlm.nih.gov/9563896